GlassScriptPhysician profile
Carmelo Diaz
NPI 1326420217
$35,001.35
in general payments reported to CMS, 2019-2025
64 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10K · 2022: $16K · 2023: $2,788 · 2024: $3,587 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,897 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,897.44 |
| Education | $251.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,416.43 | 2021-2025 | |
| Biogen, INC. | $1,545.87 | 2021-2022 | |
| Janssen Biotech, INC. | $1,191.32 | 2023-2025 | Tremfya |
| Abbott Laboratories | $1,099.89 | 2021 | |
| Amgen INC. | $1,019.82 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $889.75 | 2023-2025 | Opzelura, Opzelura, Iclusig |
| Livanova USA, INC. | $851.30 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $795.60 | 2024-2025 | Ycanth |
| Teva Pharmaceuticals USA, INC. | $692.34 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $676.18 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $642.11 | 2024-2025 | Zoryve |
| Genzyme Corporation | $578.29 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $534.09 | 2021-2022 | |
| Dermavant Sciences, INC. | $498.71 | 2023-2024 | Vtama |
| Emd Serono, INC. | $498.52 | 2021-2022 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmelo Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.